Biomarker start-up raises $7M; Miraculins markets non-invasive cholesterol test;

> The Woburn, MA-based start-up Avantra has raised $7 million in Series A cash. The company is advancing assets it acquired from Decision Biomarkers, which filed for bankruptcy late last year. Story

> Canada's Miraculins is marketing a non-invasive test that can measure cholesterol levels through the skin. Report

> Chronix Biomedical says it is accelerating its biomarker development capabilities with the installation of Germany's first state-of-the-art high-throughput DNA mass sequencer at the University of Göttingen, Chronix's long-time collaborator. Chronix release

> Advanced Cell Diagnostics has launched the RNAscope FFPE Assay Kit, a line of RUO (Research-Use-Only) products designed to detect RNA biomarkers in routine Formalin-Fixed, Paraffin-Embedded tissue specimens with single molecule sensitivity. ACD release

And Finally... Elevated levels of the enzyme alpha-amylase in saliva offer a clear biological indicator of stress, which may flag problems for any woman trying to conceive a child. Feature

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.